ABSTRACT
Encapsulating ultrasmall Cu nanoparticles inside Zr-MOFs to form core-shell architecture is very challenging but of interest for CO2 reduction. We report for the first time the incorporation of ultrasmall Cu NCs into a series of benchmark Zr-MOFs, without Cu NCs aggregation, via a scalable room temperature fabrication approach. The Cu NCs@MOFs core-shell composites show much enhanced reactivity in comparison to the Cu NCs confined in the pore of MOFs, regardless of their very similar intrinsic properties at the atomic level. Moreover, introducing polar groups on the MOF structure can further improve both the catalytic reactivity and selectivity. Mechanistic investigation reveals that the CuI sites located at the interface between Cu NCs and support serve as the active sites and efficiently catalyze CO2 photoreduction. This synergetic effect may pave the way for the design of low-cost and efficient catalysts for CO2 photoreduction into high-value chemical feedstock.
ABSTRACT
A novel stereoisomer of eushearilide, 23-demethyleushearilide, was synthesized, and the structure-activity relationships of this compound along with known eushearilide stereoisomers were investigated in order to design novel lead compounds for the treatment of fungal infections. It was discovered that all of these congeners, together with the natural product, exhibited a wide range of antimicrobial activity against not only fungi but also against bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Subject(s)
Macrolides/chemical synthesis , Macrolides/pharmacology , Phosphorylcholine/analogs & derivatives , Anti-Infective Agents/chemical synthesis , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Macrolides/chemistry , Methicillin-Resistant Staphylococcus aureus/drug effects , Microbial Sensitivity Tests , Phosphorylcholine/chemical synthesis , Phosphorylcholine/chemistry , Phosphorylcholine/pharmacology , Stereoisomerism , Vancomycin Resistance , Vancomycin-Resistant Enterococci/drug effectsABSTRACT
In this study we monitored protein dynamics in response to cisplatin, 5-fluorouracil, and irinotecan with different concentrations and administration modes using "reverse-phase" protein arrays (RPPAs) in order to gain comprehensive insight into the protein dynamics induced by genotoxic drugs. Among 666 protein time-courses, 38% exhibited an increasing trend, 32% exhibited a steady decrease, and 30% fluctuated within 24 h after drug exposure. We analyzed almost 12,000 time-course pairs of protein levels based on the geometrical similarity by correlation distance (dCor). Twenty-two percent of the pairs showed dCor > 0.8, which indicates that each protein of the pair had similar dynamics. These trends were disrupted by a proteasome inhibitor, MG132, suggesting that the protein degradation system was activated in response to the drugs. Among the pairs with high dCor, the average dCor of pairs with apoptosis-related protein was significantly higher than those without, indicating that regulation of protein levels was induced by the drugs. These results suggest that the levels of numerous functionally distinct proteins may be regulated by common degradation machinery induced by genotoxic drugs.
Subject(s)
Camptothecin/analogs & derivatives , Cisplatin/toxicity , Fluorouracil/toxicity , Mutagens/toxicity , Proteolysis/drug effects , Apoptosis , Camptothecin/toxicity , DNA Damage , HCT116 Cells , Humans , Irinotecan , Leupeptins/pharmacology , Proteasome Endopeptidase Complex/metabolism , Proteasome Inhibitors/pharmacology , Proteome/metabolismABSTRACT
Heterophyllous aquatic plants produce aerial (i.e., floating and terrestrial) and submerged leaves-the latter lack stomata-while homophyllous plants contain only submerged leaves, and cannot survive on land. To identify whether differences in morphogenetic potential and/or physiological stress responses are responsible for variation in phenotypic plasticity between two plants types, responses to abscisic acid (ABA) and salinity stress were compared between the closely related, but ecologically diverse pondweeds, Potamogeton wrightii (heterophyllous) and P. perfoliatus (homophyllous). The ABA-treated (1 or 10 µM) P. wrightii plants exhibited heterophylly and produced leaves with stomata. The obligate submerged P. perfoliatus plants were able to produce stomata on their leaves, but there were no changes to leaf shape, and stomatal production occurred only at a high ABA concentration (10 µM). Under salinity stress conditions, only P. wrightii leaves formed stomata. Additionally, the expression of stress-responsive NCED genes, which encode a key enzyme in ABA biosynthesis, was consistently up-regulated in P. wrightii, but only temporarily in P. perfoliatus. The observed species-specific gene expression patterns may be responsible for the induction or suppression of stomatal production during exposure to salinity stress. These results suggest that the two Potamogeton species have an innate morphogenetic ability to form stomata, but the actual production of stomata depends on ABA-mediated stress responses specific to each species and habitat.
Subject(s)
Abscisic Acid/pharmacology , Aquatic Organisms/physiology , Plant Stomata/physiology , Potamogetonaceae/physiology , Stress, Physiological/drug effects , Aquatic Organisms/drug effects , Aquatic Organisms/genetics , Gene Expression Regulation, Plant/drug effects , Genes, Plant , Plant Stomata/drug effects , Potamogetonaceae/anatomy & histology , Potamogetonaceae/drug effects , Potamogetonaceae/genetics , Real-Time Polymerase Chain Reaction , Salinity , Stress, Physiological/genetics , Time FactorsABSTRACT
BACKGROUND: The use of standard chemotherapy regimens has changed the application of chemosensitivity tests from all chemotherapy-eligible patients to those who have failed standard chemotherapy, which includes patients with highly advanced, relapsed, or chemoresistant tumors. METHODS: We evaluated a total of 43 advanced primary and relapsed gastric cancers for chemosensitivity based on drug dose response curves to improve the objectivity and quality of quantitative measurements. The dose response curves were classified based on seven expected patterns. Instead of a binary chemosensitivity evaluation, we ranked drug sensitivity according to curve shapes and comparison with the peak plasma concentration (ppc) of each drug. RESULTS: A total of 193 dose response curves were obtained. The overall informative rate was 67.4%, and 85.3% for cases that had a sufficient number of cells. Paclitaxel (PXL)and docetaxel tended to show a higher rank, while cisplatin (CIS) and 5-fluorouracil (5-FU) tended to show resistance, particularly among the 20 cases (46.5%) that had recurrent disease after receiving chemotherapy with CIS and S-1 (5-FU). As such, we speculate that the resistant pattern of the chemosensitivity test suggests that cells with acquired drug resistance were selected by chemotherapy. Indeed, we observed a change in the chemosensitivity pattern of a sample before and after chemotherapy in terms of PXL sensitivity, which was used after primary chemotherapy. CONCLUSIONS: These results suggest that: (i) the dose-response pattern provides objective information for predicting chemosensitivity; and (ii) chemotherapy may select resistant cancer cell populations as a result of the therapy.
Subject(s)
Antineoplastic Agents/pharmacology , Ascites/drug therapy , Cell Proliferation/drug effects , Neoplasm Recurrence, Local/drug therapy , Stomach Neoplasms/classification , Stomach Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Ascites/pathology , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Stomach Neoplasms/pathology , Tumor Cells, Cultured , Young AdultABSTRACT
BACKGROUND: Paradoxically, Helicobacter pylori-positive (HP+) advanced gastric cancer patients have a better prognosis than those who are HP-negative (HP-). Immunologic and statistical analyses can be used to verify whether systemic mechanisms modulated by HP are involved in this more favorable outcome. METHODS: A total of 658 advanced gastric cancer patients who underwent gastrectomy were enrolled. HP infection, mismatch repair, programmed death-ligand 1 (PD-L1) and CD4/CD8 proteins, and microsatellite instability were analyzed. Overall survival (OS) and relapse-free survival (RFS) rates were analyzed after stratifying clinicopathological factors. Cox proportional hazards regression analysis was performed to identify independent prognostic factors. RESULTS: Among 491 patients that were analyzed, 175 (36%) and 316 (64%) patients were HP+ and HP-, respectively. Analysis of RFS indicated an interaction of HP status among the subgroups for S-1 dose (Pinteraction = .049) and PD-L1 (P = .02). HP+ patients in the PD-L1- group had statistically higher 5-year OS and RFS than HP- patients (81% vs 68%; P = .0011; hazard ratio [HR] = 0.48, 95% confidence interval [CI] = 0.303 to 0.751, and 76% vs 63%; P = .001; HR = 0.508, 95% CI = 0.335 to 0.771, respectively). The 5-year OS and RFS was also statistically higher for HP+ compared with HP- patients in the "PD-L1- and S-1-r educed" group (86% vs 46%; P = .001; HR = 0.205, 95% CI = 0.07 to 0.602, and 83% vs 34%; P = .001; HR = 0.190, 95% CI = 0.072 to 0.498, respectively). Thus, HP status was identified as one of the most potentially important independent factors to predict prolonged survival. CONCLUSION: This retrospective study suggests that an HP-modulated host immune system may contribute to prolonged survival in the absence of immune escape mechanisms of gastric cancer.
Subject(s)
Helicobacter pylori , Stomach Neoplasms , B7-H1 Antigen/metabolism , Chemotherapy, Adjuvant , Humans , Neoplasm Recurrence, Local/pathology , Prognosis , Retrospective Studies , Stomach Neoplasms/drug therapy , Stomach Neoplasms/metabolism , Stomach Neoplasms/surgeryABSTRACT
Indocyanine green (ICG) is specifically excreted through the biliary tracts. The authors applied ICG as a carrier of gemcitabine (GEM) to devising a novel drug delivery system. Our newly devised chitin flakes, ICG and GEM were mixed together. Then physiological saline solution was added to the mixture to form the system. The release profiles of GEM and ICG from the system were examined at various times in vitro. Anticancer activities of the GEM and ICG delivered from the system were detected by MTT assay method using human pancreatic cancer cell lines. The novel system was visco-elastic green sol at room temperature and changed to gel at body temperature. Seventy to 80% of GEM was gradually delivered from the system in 24 hours, and 30 to 50% of ICG was slowly released over 24 hours. The released GEM favorably demonstrated anticancer activities against the cancer cells, while the ICG released from the system showed no oncolytic activities. These suggested that our devised system would be clinically useful as a novel tool in cancer chemotherapy.
Subject(s)
Deoxycytidine/analogs & derivatives , Pancreatic Neoplasms/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Deoxycytidine/chemistry , Deoxycytidine/pharmacology , Humans , Pancreatic Neoplasms/drug therapy , Pharmaceutical Solutions/chemistry , GemcitabineABSTRACT
The authors used 70% deacetylated chitin and cisplatin (CDDP) to devise a novel anticancer drug delivery system (DDS). We examined in vitro release of the CDDP from the system. The novel system was intraperitoneally( ip) given to malignant ascites-bearing mice, and the survival time of each animal was recorded. The related oncolytic mechanism was immunologically investigated. More than 70-90% of the CDDP was gradually delivered from the system in 24 hours. Nineteen animals among 30 treated with our system survived for longer than 4 weeks, and a recurrence of ascites was nil. A 4- week survival rate of the animals with ip injected conventional CDDP was 5/14. All non-treated animals had massive ascites and died within 4 weeks. Immunologic studies suggested that cytotoxic immunoresponse was induced in the mice treated with the novel system. Our newly devised system warrants for clinical applications in the treatment of malignant ascites.
Subject(s)
Antineoplastic Agents/administration & dosage , Ascites/drug therapy , Cisplatin/administration & dosage , Peritoneal Neoplasms/drug therapy , Animals , Antineoplastic Agents/therapeutic use , Ascites/etiology , CD8-Positive T-Lymphocytes/immunology , Cell Line, Tumor , Cisplatin/therapeutic use , Drug Delivery Systems , Injections, Intraperitoneal , Mice , Neoplasm Transplantation , Peritoneal Neoplasms/complications , Peritoneal Neoplasms/immunologyABSTRACT
To develop an efficient CO2 reduction catalyst, hybridizing a molecular catalyst and a porous coordination polymer (PCP) is a promising strategy because it can combine both advantages of the precise reactivity control of the former and the CO2 adsorption property of the latter. Although several PCP hybrid catalysts have been reported to date, the CO2 sorption behavior and the CO2 reduction reactivity have been investigated separately, and the CO2 enrichment during the catalysis is still unclear. We report CO2 photoreduction under different temperatures and pressures using a PCP-RuII complex hybrid catalyst. The product selectivity (CO or HCOOH) varied depending on the reaction conditions. The altered selectivity could be interpreted in terms of the CO2 capture in the micropores of a PCP.
ABSTRACT
A depsipeptidic analogue of FE399 was efficiently synthesized mainly through macrolactamization using 2-methyl-6-nitrobenzoic anhydride (MNBA), and a detailed investigation of the desired 16-membered macrolactam core of FE399 was performed. It was determined that the combination of MNBA and a catalytic amount of 4-(dimethylamino)pyridine N-oxide exhibits much higher activity than that of conventionally used coupling reagents such as hexafluorophosphate azabenzotriazole tetramethyl uronium and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate.
ABSTRACT
The authors devised two different types of cisplatin (CDDP) delivery systems; namely, System A and System B. The anticancer efficacy with each system was examined using cancer-bearing animals. Seventy-percent deacetylated chitin (DAC-70) was used as the drug carrier in the system. Cancer-bearing animals were prepared by intra-peritoneally (ip) inoculating the MM-46 cancer cells to C3H mice. Each novel system was also ip injected to the cancer-bearing mouse, and then survival time of each animal was recorded to evaluate the anti-cancer efficacy of the system. Both Systems A and B were viscoelastic sol at 25°C and slowly changed to gel at 37°C. Four-week survival rate of each animal treated with the System was as follows: System A 6/10 (60%), System B 10/11 (90.9%), conventional CDDP alone 3/9 (33.3%) and non-treated 0/7 (0%). No signs of recurrence of ascites were encountered in the long-term survived animals treated with System A and B. Our newly devised systems provided a favorable antitumor efficacy in vivo. Now, we will carry out further studies by making a clinically applicable novel conjugated system, DAC-70 and CDDP.
Subject(s)
Antineoplastic Agents/administration & dosage , Cisplatin/administration & dosage , Animals , Drug Delivery Systems , Mice , Mice, Inbred C3H , Neoplasms, Experimental/drug therapy , TabletsABSTRACT
Spectroscopic studies were carried out on chlorophyll a and cobalt(II)tetraphenylporphyrin solubilized in a poly(L-glutamate) (Poly(Glu))-decylammonium chloride (DeAC) complex system, in the presence of methylviologen (MV2+). The cooperative binding occurred between the anionic Poly(Glu) and the cationic DeAC, leading to the formation of micelle-like hydrophobic clusters of DeAC and also the change in conformation of the Poly(Glu) from the random coil to the alpha-helix. All of the absorption spectra, the fluorescence quantum yields and the fluorescence lifetimes indicated the existence of equilibrium between the aggregated biofunctional molecules in the bulk phase and the monomeric species in the complex phase of the Poly(Glu)-DeAC solution. The fluorescence quenching of the biofunctional molecules by methylviologen indicates that the conformation-dependent electron transfer occurs in the complex phase.
Subject(s)
Chlorophyll/chemistry , Cobalt/chemistry , Photochemistry , Porphyrins/chemistry , Amines/chemistry , Hydrophobic and Hydrophilic Interactions , Ions , Micelles , Molecular Conformation , Polyglutamic Acid/chemistry , Spectrum AnalysisABSTRACT
Cancer relapse occurs with substantial frequency even after treatment with curative intent. Here we studied drug-tolerant colonies (DTCs), which are subpopulations of cancer cells that survive in the presence of drugs. Proteomic characterization of DTCs identified stemness- and epithelial-dominant subpopulations, but functional screening suggested that DTC formation was regulated at the transcriptional level independent from protein expression patterns. We consistently found that α-amanitin, an RNA polymerase II (RNAPII) inhibitor, effectively inhibited DTCs by suppressing TAF15 expression, which binds to RNA to modulate transcription and RNA processing. Sequential administration of α-amanitin and cisplatin extended overall survival in a cancer-relapse mouse model, namely peritonitis carcinomatosa. Therefore, post-treatment cancer relapse may occur through non-distinct subpopulations and may be effectively prevented by α-amanitin to disrupt transcriptional machinery, including TAF15.
Subject(s)
Alpha-Amanitin/administration & dosage , Drug Resistance/drug effects , Enzyme Inhibitors/administration & dosage , Peritoneal Neoplasms/drug therapy , TATA-Binding Protein Associated Factors/metabolism , Alpha-Amanitin/pharmacology , Animals , Cell Line, Tumor , Cisplatin/administration & dosage , Cisplatin/therapeutic use , Down-Regulation , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , HCT116 Cells , HT29 Cells , HeLa Cells , Humans , MCF-7 Cells , Mice , Peritoneal Neoplasms/genetics , Peritoneal Neoplasms/metabolism , Proteomics/methods , Secondary Prevention , Transcription, Genetic/drug effects , Xenograft Model Antitumor AssaysABSTRACT
To confirm the clinical significance of NF-κB and JNK protein expression from experimentally identified candidates for predicting prognosis for patients with 5-FU treatment, we evaluated the protein expression of surgically removed specimens. A total of 79 specimens were obtained from 30 gastric and 49 colorectal cancer patients who underwent R0 resection followed by postoperative 5-FU based adjuvant chemotherapy. Immunohistochemical examinations of NF-κB and JNK on tissue microarrays (TMAs) revealed that significantly shorter time-to-relapse (TTR) in both NF-κB(+) and JNK(-) subgroups in both gastric (NF-κB(+), p = 0.0002, HR11.7. 95%CI3 3.2-43.4; JNK(-), p = 0.0302, HR4.4, 95%CI 1.2-16.6) and colon (NF-κB(+), p = 0.0038, HR36.9, 95%CI 3.2-426.0; JNK(-), p = 0.0098, HR3.2, 95%CI 1.3-7.7) cancers. These protein expression patterns also show strong discriminately power in gastric cancer patients for overall survival rate, suggesting a potential utility as prognostic or chemosensitivity markers. Baseline expression of these proteins using gastric cancer cell lines demonstrated the reciprocal patterns between NF-κB and JNK, while 5-FU exposure of these cell lines only induced NF-κB, suggesting that NF-κB plays a dominant role in the response to 5-FU. Subsequent siRNA experiments confirmed that gene knockdown of NF-κB increased 5-FU-specific sensitivity, whereas that of JNK did not affect the chemosensitivity. These results suggest that the expression of these proteins may aid in the decisions involved with adjuvant chemotherapy for gastrointestinal tract cancers.
Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Biomarkers, Tumor/metabolism , Chemotherapy, Adjuvant/methods , Colorectal Neoplasms/drug therapy , Fluorouracil/pharmacology , Gene Expression Regulation, Neoplastic , Stomach Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Cell Line, Tumor , Cluster Analysis , Colorectal Neoplasms/metabolism , Humans , Immunohistochemistry/methods , MAP Kinase Kinase 4/metabolism , Middle Aged , Prognosis , RNA, Small Interfering/metabolism , Recurrence , Stomach Neoplasms/metabolismABSTRACT
BACKGROUND: The binding of EGFR and its ligands leads to autophosphorylation of receptor tyrosine kinase as well as subsequent activation of signal transduction pathways that are involved in regulating cellular proliferation, differentiation, and survival. An EGFR inhibitor, cetuximab binds to EGFR and consequently blocks a variety of cellular processes. KRAS/BRAF mutations are known to be associated with a low response rate to cetuximab. In the present study, to clarify the anti-tumor mechanisms of cetuximab, we evaluated the KRAS/BRAF status, phosphorylation level of the EGFR pathway, and the tumor suppression effect in vivo, using a human colon cancer cell line HT29, which exhibited the highest EGFR expression in response to the cetuximab therapy among the 6 colorectal cancer cell lines tested. FINDINGS: The conventional growth suppression assay did not work efficiently with cetuximab. EGF, TGF-α, and IGF activated the EGFR/MAPK cell signaling pathway by initiating the phosphorylation of EGFR. Cetuximab partially inhibited the EGFR/MAPK pathway induced by EGF, TGF-α, and IGF. However, cetuximab exposure induced the EGFR, MEK, and ERK1/2 phosphorylation by itself. Mouse xenograft tumor growth was significantly inhibited by cetuximab and both cetuximab-treated and -untreated xenograft specimens exhibited phosphorylations of the EGFR pathway proteins. CONCLUSIONS: We have confirmed that cetuximab inhibited the EGFR/MAPK pathway and reduced tumor growth in the xenografts while the remaining tumor showed EGFR pathway activation. These results suggest that: ( i ) The effect of cetuximab in growth signaling is not sufficient to induce complete growth suppression in vitro; ( ii ) time-course monitoring may be necessary to evaluate the effect of cetuximab because EGFR signaling is transmitted in a minute order; and ( iii ) cetuximab treatment may have cells acquired resistant selectively survived in the heterogeneous cancer population.
ABSTRACT
Hydrogen production was accomplished under visible-light irradiation by using a system consisting of a biomolecule (chlorophyll a), methylviologen, ethylenediaminetetraacetic acid disodium salt and Pt-loaded poly(l-glutamate) (Poly(Glu)), in aqueous decylammonium chloride (DeAC) solution. Spectroscopic studies revealed that chlorophyll a is solubilized in the hydrophobic clusters of Pt-loaded Poly(Glu)-decylammonium chloride. In the Poly(Glu)-DeAC complex, the electron transfer occurred between chlorophyll a and methylviologen leading to hydrogen production. The most noticeable result is that the rate of hydrogen evolution depends on the change from the random coil to the alpha-helix in conformation of Poly(Glu) induced by the cooperative binding with DeAC.
Subject(s)
Hydrogen/radiation effects , Light-Harvesting Protein Complexes/radiation effects , Light , Polyglutamic Acid/radiation effects , Amines/chemistry , Circular Dichroism , Electron Transport , Hydrogen/chemistry , Hydrophobic and Hydrophilic Interactions , Light-Harvesting Protein Complexes/chemistry , Photochemistry , Platinum/chemistry , Platinum/radiation effects , Polyglutamic Acid/chemistry , Protein Structure, Secondary/radiation effects , Sensitivity and Specificity , Solubility , Solutions/chemistry , Spectrometry, Fluorescence , Time Factors , Water/chemistryABSTRACT
Intravenous human immunoglobulin therapy infrequently results in excessive inflammatory responses in vivo; these effects are not fully understood. We assessed whether sulfonated human immunoglobulin (SHIG) or polyethylene glycol-treated human immunoglobulin (PHIG) enhanced expression of inflammatory receptors on peripheral blood neutrophils in vitro, such as alphaMbeta2 (CD11b/CD18) and Fc gamma receptor type III (FcgammaRIII). CD11b and CD16 expression on neutrophils was measured by fluorescence flow cytometry. Various cytokines were assessed using a highly sensitive fluorescence microsphere system. SHIG enhanced/induced CD11b expression and partial aggregations on neutrophils, but PHIG did not. No detection of aggregation IgG was observed in SHIG and PHIG. SHIG-induced CD11b expression was inhibited by treatment of corticosteroid (dexamethasone) and by anti-CD16 monoclonal antibody. Concentrations of various cytokines such as interleukin (IL)-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, RANTES, tumor necrosis factor (TNF)-alpha, and interferon (INF)-gamma in culture supernatant were not significantly changed by SHIG or PHIG. SHIG and PHIG did not enhance CD16 on neutrophils. SHIG enhanced CD16-linked CD11b expression on neutrophils in vitro. CD11b induction was inhibited by dexamethasone and by anti-CD16 antibody. These in vitro results suggest that aggregations and enhancement of CD11b on neutrophils by SHIG may induce excessive inflammatory responses in vivo.